Sign in

    Arseniy Shabashvili • Guggenheim Securities

    Arseniy Shabashvili's questions to Travere Therapeutics Inc (TVTX) leadership

    Arseniy Shabashvili's questions to Travere Therapeutics Inc (TVTX) leadership • Q2 2025

    Question

    Arseniy Shabashvili of Guggenheim Securities asked about the medical community's reception to new data from the SPARTAN studies and whether further real-world or biomarker data is anticipated to support Filspari's positioning as a disease-modifying therapy.

    Answer

    Dr. Jula Inrig, Chief Medical Officer, reported a very positive reception, with excitement around data showing Filspari's efficacy in combination with SGLT2 inhibitors and its effect on disease-modifying biomarkers. She confirmed plans to validate these findings using the large Phase 3 study biomarker set and present that data at future congresses.

    Ask Fintool Equity Research AI

    Arseniy Shabashvili's questions to Travere Therapeutics Inc (TVTX) leadership • Q3 2024

    Question

    In a follow-up, Arseniy Shabashvili of Guggenheim Securities asked about FILSPARI's uptake among community-based nephrologists versus academic thought leaders, and whether the message is reaching a broader physician base post-full approval.

    Answer

    Chief Commercial Officer Peter Heerma responded that while it's still early post-full approval, the commercial strategy targets a broad base of ~6,000 nephrologists to reach the majority of patients, who reside in the community. He confirmed that prescription patterns show the majority of uptake is from community physicians, while also noting strong, positive feedback from academic leaders, especially with the support of the new KDIGO guidelines.

    Ask Fintool Equity Research AI